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Aims: Inhibition of neutral endopeptidases (NEP) results in a beneficial increase in plasma concentrations of
natriuretic peptides such as ANP. However NEP inhibitors were ineffective anti-hypertensives, probably be-
cause NEP also degrades vasoconstrictor peptides, including endothelin-1 (ET-1). Dual NEP and endothelin
converting enzyme (ECE) inhibition may be more useful. The aim of the study was to determine whether
SLV-306 (daglutril), a combined ECE/NEP inhibitor, reduced the systemic conversion of big ET-1 to the
mature peptide. Secondly, to determine whether plasma ANP levels were increased.
Main methods: Following oral administration of three increasing doses of SLV-306 (to reach an average target
concentration of 75, 300, 1200 ng ml−1 of the active metabolite KC-12615), in a randomised, double blinded
regime, big ET-1 was infused into thirteen healthy male volunteers. Big ET-1 was administered at a rate of
8 and 12 pmol kg−1 min−1 (20 min each). Plasma samples were collected pre, during and post big ET-1
infusion. ET-1, C-terminal fragment (CTF), big ET-1, and atrial natriuretic peptide (ANP) were measured.
Key findings: At the two highest concentrations tested, SLV-306 dose dependently attenuated the rise in blood
pressure after big ET-1 infusion. There was a significant increase in circulating big ET-1 levels, compared with
placebo, indicating that SLV-306 was inhibiting an increasing proportion of endogenous ECE activity. Plasma
ANP concentrations also significantly increased, consistent with systemic NEP inhibition.
Significance: SLV-306 leads to inhibition of both NEP and ECE in humans. Simultaneous augmentation of ANP
and inhibition of ET-1 production is of potential therapeutic benefit in cardiovascular disease.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The success of angiotensin converting enzyme (ACE) inhibitors as a
treatment for chronic heart failure (CHF), myocardial infarction, hyper-
tension and atherosclerotic disease has demonstrated the therapeutic
value of neurohumoral manipulation using inhibitors of vasoactive
enzymes (Garg and Yusuf, 1995; Flather et al., 2000; Yusuf et al., 2000).
Neutral endopeptidase (NEP) degrades natriuretic peptides and
NEP inhibition increases plasma concentrations of atrial and brain
natriuretic peptide (ANP and BNP) (Northridge et al., 1989). ANP
and BNP have hemodynamic, neurohumoral and growth effects that
might be of therapeutic benefit in CHF, hypertension and atheroscle-




-NC-ND license.also metabolises angiotensin II and endothelin-1 (ET-1), effects that
may counteract the potential benefits of increased natriuretic peptides
(Ando et al., 1995; Richards et al., 1993).
Two distinct therapeutic strategies have emerged to block the
unwanted action of endothelin-1 (ET-1) in pathophysiological condi-
tions, receptor antagonists (Palmer, 2009; Davenport, 2002; Davenport
and Maguire, 2006; Dhaun et al., 2007; Vachiéry and Davenport, 2009;
Davenport andMaguire, 2011) and inhibitors of the endothelin convert-
ing enzymes (ECE-1, Xu et al., 1994 and ECE-2, Emoto and Yanagisawa,
1995), the major synthetic pathway in the human vasculature (Russell
and Davenport, 1999). Using electronmicroscopy ECE has been localised
primarily to the intracellular compartments of human endothelial cells
(Russell et al., 1998a,b). However, some Big-ET-1 escapes intracellular
conversion and circulates in plasma (Naruse et al., 1991). Water-
soluble solutes such as transmitters have been shown to move across
endothelial cells from the plasma through gap junctions to the underlying
smoothmuscle. However, big ET-1 does not bind to vascular ET receptors
until cleaved to ET-1 by converting enzymes present on smooth muscle
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human vessels with atherosclerosis (Maguire and Davenport, 1998)
suggesting that conversion of big ET-1 to ET-1 by smooth muscle ECE
may contribute to increased plasma/tissue ET levels in disease.
Conversion has been imaged in vivo by infusion of [18F]-big ET-1 to
quantify tissue specific conversion to [18F]-ET-1 which bound to ETA
receptors on the vascular smooth muscle (Johnstrom et al., 2010).
This was significantly reduced by phosphoramidon, an inhibitor of
ECE and NEP,which does not cross the plasmamembrane and therefore
cannot inhibit endothelial cell ECE but is consistent with inhibition of
enzyme conversion by vascular smooth muscle and subsequent reduc-
tion of [18F]-ET-1 receptor binding (Johnstrom et al., 2010).
To date, orally active dual inhibitors of both NEP and ECE have
been developed, rather than purely ECE selective compounds (Dive
et al., 2009; Battistini et al., 2005). Combined NEP and ECE inhibition,
leading to augmented natriuretic peptide concentrations, coupled
with reduced ET-1 synthesis is an attractive therapeutic strategy in
a range of cardiovascular diseases. Following oral administration,
SLV-306 (daglutril) is hydrolysed to the active metabolite KC-12615
(Dickstein et al., 2004), a new chemical entity which is a mixed en-
zyme inhibitor of both ECE and NEP. The inhibitor has not been exten-
sively studied but in diabetic rats, SLV-306 has been shown to reduce
proteinuria and urinary albumin excretion (Thöne-Reinke et al., 2004).
SLV-306 reduced pulmonary pressures in patients with chronic heart
failure (Dickstein et al., 2004) and a Phase II trial has been completed
for the treatment of essential hypertension and congestive heart failure
(Bayes et al., 2003; Tabrizchi, 2003). The compound had no effect on al-
buminuria, but reduces day and night-time systolic blood pressure and
night-time diastolic blood pressure on top of losartan in albuminuric
type II diabetic patients (Van der Meer et al., 2011). The aim of the
study was to characterise orally active, dual NEP and ECE inhibitor to
demonstrate systemic ECE and NEP inhibition in healthy volunteers.
Materials and methods
SLV-306 and KC-12615
Following oral administration of SLV-306 it is quickly absorbed
and hydrolysed to the active metabolite KC-12615 (Dickstein et al.,
2004; Tabrizchi, 2003) which in enzyme assays is a potent NEP-
inhibitor (IC50=4.2 nM) with additional inhibitory activity on two
endothelin-converting enzymes, ECE-1 (IC50=1.5 μM, comparable
with 0.3 μM for phosphoramidon).
In vivo studies in healthy volunteers
Studieswere approvedby thehospital ethics committee and all volun-
teers gave written informed consent. There were two parts to this study.
Part 1 Owing to a high inter-subject variability in the plasma concen-
trations of SLV-306 and KC-12615, a concentration controlled
design was used. Twenty nine male volunteers attended for
the first stage of the study which involved taking two different
doses of SLV-306 (400mg (n=29), and 600 mg (n=6) or
800 mg (n=23)) at least seven days apart. Blood samples
were collected after dosing for measurement of plasma concen-
trations of KC-12615. Pharmacokinetic modelling was used to
calculate the individual doses of SLV-306 needed to achieve av-
erage plasma concentrations over the first 6 h of KC-12615 of
approximately 75 ngml−1, 30 ng ml−1 and 1200 ngml−1.
Part 2 Fifteen male volunteers (mean age 22, range 18–38 years)
were selected from the initial screen andattended for the second
part of the studywhich involved four further visits at least seven
days apart. For these, volunteers attended the clinical laboratory
at 08.00 h, having fasted frommidnight. An intravenous cannula
was placed in each forearm. After 1 h of supine rest, baselineblood pressure and heart rate recordings were made and blood
samples were taken (see below). Each subject then received
either placebo or a single oral dose of SLV-306, as calculated
individually from the pharmacokinetic analysis in the first
part of the study. The selected dose of SLV306 varied from 44
to 258 mg (mean 165 mg) for the low target level, from 150 to
375 mg (mean 223 mg) for the medium level, and from 4504
to 1500 mg (mean 1862 mg) for the high level. A double-blind
ascending dose protocol with random insertion of placebo was
used to assign treatment. 160 min after dosing, a 20 minute in-
fusion of 8 pmol kg−1 min−1 of big ET-1 was administered
(Fig. 1). After a further 40 min a second 20 minute infusion of
12 pmol kg−1 min−1 of big ET-1 was given (i.e. between 220
and 240 min post-dosing). The doses of big ET-1 were chosen
from pilot studies, as ones likely to lead to a rise in mean
arterial pressure of approximately 20 mm Hg. The timing of
the infusions was chosen to coincide with peak plasma concen-
trations of KC-12615 as demonstrated in the pharmacokinetic
first stage of the in vivo studies.
Measurements of arterial pressure and heart rate
Heart rate and arterial pressure were measured using an automated
blood pressure recorder (Dinamap 1846 SX, Critikon Inc., Tampa, Florida,
USA). Measurements were made before the intake of study drug and
frequently thereafter (Fig. 1).
Blood samples for neurohumoral measurements
Venous blood (11 ml) was collected from the contralateral forearm
into chilled tubes at baseline and 160, 210, 240, 260, 280, 300 and
360 min after administration of study drug (Fig. 1). Sample handling
and processing has been described previously as have the assays used
tomeasure ANP (McDonagh et al., 1998), big ET-1 and the two cleavage
products resulting from ECE activity, ET-1 and the C-terminal fragment
(CTF) (Plumpton et al., 1995).
Statistical methods
The treatment groups were compared using a two-way Analysis of
Variance (ANOVA) with factors for treatment group, study period and
subjects. In addition, least square mean changes were calculated for
each treatment group and the three, SLV-306 minus placebo differ-
ences were estimated. Each of the three comparisons was performed
at the 5% significance level, without adjustment for multiple testing.
Results
In vivo studies in healthy volunteers
Of the 15 volunteers taking part in the big ET-1 infusion studies, 1
withdrew for personal reasons and 1 was withdrawn because of an
excessive rise in blood pressure (30 mm Hg) and fall in heart rate
(−15 beats min−1). No subjects experienced any significant adverse
event.
Plasma concentrations of KC-12615
Maximum plasma concentrations of KC-12615 are achieved at
about 3–4 h following oral dosing of SLV-306. The low, medium and
high doses of SLV-306 resulted in clearly distinguishable plasma
concentrations of KC-12615. The respective mean steady state
concentrations were 26, 216 and 1435 ng ml−1.
Arterial pressure
The rise in systolic, and diastolic arterial pressure following big
ET-1 infusion is shown in Fig. 2. SLV-306 caused a concentration
Fig. 1. In vivo study protocol. Subjects rested supine for 60 min before intake of study medication. The first big ET-1 infusion was commenced 160 min after dosing and the second
after 220 min. Δ=neurohumoral, ▲=blood pressure and Ο=pharmacokinetic measurements.
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mean peak (±standard error, SE) increases in systolic, diastolic and
mean arterial pressurewere 19.2 (2.1), 16.1 (1.5) and 15.9 (1.6)mmHg
after placebo pre-treatment. The increases after 75 ng ml−1 were,
18.3 (3.0), 14.0 (2.1) and 15.0 (2.3) mm Hg, respectively. The respec-
tive increases after 300 ngml−1 were 15.5 (2.5), 13.3 (1.7) and 13.5
(1.9) mm Hg. Those after 1200 ng ml−1 were 10.4 (2.8), 10.5 (2.0) and
9.0 (2.1) mm Hg, respectively. The differences between placebo and
1200 ng ml−1 were all significant for systolic, diastolic, and mean
arterial pressure.
Heart rate
SLV-306 caused an inhibition of the reflex bradycardia induced by
big ET-1 infusion (Fig. 2). During big ET-1 infusion, the mean peakFig. 2. Change in (a) systolic, (b) diastolic and (c) mean arterial pressures, from baseline, du
with placebo or SLV-306, to give KC-12615 plasma concentrations of approximately 75, 300 a
made prior to commencement of the first big ET-1 infusion. Change in heart rate (d) is sho
dash and open circle); 75 ng/ml (medium dashed line and open square, 300 (short dasheddecreases in heart rate were 12.1 (1.1), 11.2 (1.5), 10.2 (1.2) and
7.9 (1.4) beats per minute after pre-treatment with placebo, 75, 300
and 1200 ng ml−1, respectively.
Big ET-1, ET-1 and CTF
Basal levels of big ET-1 at time 0, before any infusions were 1.5
(0.4) for placebo and 3.0 (1.1), 2.1 (0.6) and 1.5 (0.4) pmol/l for 75,
300, and 1200 ng ml−1 respectively.
SLV-306 caused a concentration dependent increase in plasma big
ET-1 concentrations during and after the big ET-1 infusions (Fig. 3).
The mean (SE) increases in plasma big-ET in the first hour following
the completion of the big-ET infusions after treatment with placebo
or 75, 300, and 1200 ng ml−1 were 96.3 (18.3), 128.6 (25.8), 184.4
(21.6) and 216.1 (24.3) pmol l−1. The between group differencesring and after big ET-1 infusion on each of the four study days i.e. after pre-treatment
nd 1200 ng/ml. “Baseline”was the average of the last 3 arterial pressure measurements
wn in the same way. In all graphs, the treatments are shown as follows: placebo (long
line and open triangle) and 1200 ng/ml (solid line and solid squares).
Fig. 3. Changes in plasma Big ET-1, ET-1, CTF and ANP peptide levels in response to in-
creasing concentrations of KC-12615 (the active metabolite of SLV-306) following oral
dosing with placebo or SLV-306 and subsequent infusion of big ET-1. Each value repre-
sents the mean increase in plasma levels (± standard error) measured in 13 volunteers
in the first hour following completion of the big ET-1 infusion in either placebo (repre-
senting mean basal conversion indicated by horizontal line) and each of the increasing
doses. There was a significant dose dependent rise in big ET-1 (*pb0.005), (compared
with placebo, two way analysis of variance, ANOVA, with adjustment for multiple com-
parisons, pb0.005) consistent with inhibition of ECE, and a rise in ANP, consistent with
inhibition of NEP activity. In the presence of the highest two doses of SLV-306, a small
increase in the CTF was observed but ET-1 levels were unaltered.
Fig. 4. Schematic diagram showing the synthesis of ET-1 by endothelin converting
enzymes (ECE-1 and ECE-2) in the constitutive pathway and by ECE-1 in the regulated
pathway within endothelial cells of the human vasculature. Some big ET-1 escapes con-
version and is cleaved by smooth muscle cell ECE. It is proposed that following exoge-
nous infusion of big ET-1, the precursor is converted to ET-1 principally by smooth
muscle ECE which is the main target for inhibition by the active metabolite of SLV-306.
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1200 ng ml−1 doses: 88.1 (28.6) [p=0.004] and 119.9 (29.6) pmol/l
[p=0.0003], respectively.
There was no evidence of any between group differences for plasma
ET-1 levels during the same period.
Basal levels of ET-1 at time 0, before any infusions were 3.3 (0.6)
for placebo and 2.8 (0.3), 4.0 (0.4) and 2.9 (0.6) pmol/l for 75, 300,
and 1200 ng ml−1 respectively. In the placebo group, at the end of
the second infusion of big ET-1, plasma ET-1 immunoreactivity was
increased more than three fold above basal to 11.4 (5.3). The ratio
of big ET-1 to ET-1 increased in a concentration dependent manner
consistent with systemic ECE inhibition preventing metabolism of
the enzyme substrate (big ET-1) to its active metabolite (ET-1) (Fig. 3).
The mean (SE) ratio of plasma big-ET-1/ET-1 concentration increased
in a concentration dependent manner following the big ET-1 infusion:
21.6 (3.0), 20.1 (4.2), 34.1 (3.5), and 41.5 (3.9) after placebo, 75, 300
and 1200 ng ml−1, respectively. The between group differences versus
placebo were statistically significant for the 300 ng/ml and 1200 ng/ml
doses: 12.5 (4.6) [p=0.011] and 20.0 (4.8) [p=0.0002], respectively.
In the placebo group, levels of the CTF increased an order of mag-
nitude above basal confirming a proportion of the infused big ET-1
was being selectively converted as expected. In the presence of the
highest two doses of SLV 306, a small increase in the CTF was ob-
served, consistent with our previous studies with the dual NEP/ECE
inhibitor, phosphoramidon (Plumpton et al., 1995) since CTF is also
a substrate for metabolism by NEP and inhibition of this enzyme by
SLV-306 may reduce proteolysis.Atrial natriuretic peptide (ANP)
SLV-306 led to a concentration dependent increase in plasma ANP
concentrations (Fig. 3), consistent with systemic NEP inhibition. The
mean peak (SE) increases in plasma ANP after placebo, 75, 300 and
1200 ng/mlwere 4.3 (0.5), 6.6 (0.7), 7.9(0.6) and9.3 (0.7) pmol/l , respec-
tively. The between-group differences for 300 ng/ml and 1200 ng/ml
compared to placebo were statistically significant (pb0.05).
Discussion
SLV-306 and its active metabolite have in vivo actions consistent
with inhibition of both NEP and ECE. At the two highest concentra-
tions tested, SLV-306 dose dependently attenuated the rise in blood
pressure after big ET-1 infusion. There was a significant increase in
circulating big ET-1 levels, compared with placebo, indicating that
SLV-306 was inhibiting an increasing proportion of endogenous ECE
activity. Plasma ANP concentrations were also significantly increased,
consistent with systemic NEP inhibition.
NEP is also thought to metabolise ET-1 to biologically inactive
fragments, therefore treatment with SLV-306 might be predicted to
cause a rise in ET-1. Importantly, despite inhibition of NEP activity,
there was no increase in levels of the mature peptide in these volun-
teers. This can be explained by our current model of conversion of big
ET-1 (Fig. 4), where infused big ET-1 is converted by extracellular
ECE, principally located on the smooth muscle cells and immediately
binds to ETA receptors to cause vasoconstriction. The lack of change of
plasma ET-1 is likely to represent a combination of ECE inhibition re-
ducing big ET-1 conversion, with any rise in ET-1 resulting from NEP
inhibiting metabolism of the mature peptide balanced by clearing and
internalisation from the circulation via ETB receptors, mainly located
on endothelial cells. Despite the increased big ET-1 infused into the
control group, plasma levels of ET-1 are not increased but kept within
a narrow range by these physiological mechanisms. These results sug-
gest that in the presence of SLV-306, the biologically active peptide
can continue to be removed beneficially from the circulation by ETB
clearing receptors, which may represent a therapeutic advantage
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sub-types.
Conversely, it might be expected that there would be a significant
decrease in plasma ET-1 and CTF, particularly at the higher doses of
inhibitor. There are a number of possible explanations, why this was
not detected. Although the plasma concentration of the active metabo-
lite (KC-12615) at the highest dose tested, would be predicted to inhibit
most of the activity of extracellular smooth muscle ECE, based on EC50
values in vitro, the compound may not have crossed the plasma mem-
brane of endothelial cells at sufficiently high concentrations to inhibit
the continuous formation of ET-1 from the constitutive intracellular
pathway (Russell et al., 1998a).
A third possibility is that a proportion of the basal ET-1 was
formed by an alternative synthetic pathway. Intriguingly, significant
amounts of ET-1 were detectable in the ECE-1/ECE-2 double-knock-
out mouse embryos suggesting other proteases are involved in ET-1
synthesis (Yanagisawa et al., 2000). One candidate is the serineprotease
chymase present in mast cells. This enzyme cleaves the Tyr31–Gly 32
peptide bond of big ET-1 to generate ET-1(1–31), which is in turn con-
verted to ET-1 (Fecteau et al., 2005; D'Orleans-Juste et al., 2008). Impor-
tantly, ET-1(1–31) was equipotent compared with big ET-1 in causing
vasoconstriction in human isolated vessels, including coronary arteries,
and this was associated with the appearance of measurable levels of
ET-1 in the bathingmedium, consistent with conversion to the mature
peptide. Vasoconstriction was fully blocked by ETA selective antago-
nists, reflecting the predominance of the ETA receptor on vascular
smooth muscle (Maguire et al., 2001). Mast cell chymase is associated
with interstitial spaces with the potential to convert circulating big
ET-1 and provide a further source of ET-1. In addition, chymase also
generates the intermediate ET-2(1–31) which is in turn converted
to the mature peptides by an as yet uncharacterised mechanism. In-
terestingly chymase inhibitors appear more efficient in blocking big
ET-2 conversion at least in primates. The radioimmunoassay used in
the study cross-reacted equally well with mature ET-2 and any pep-
tide formed by this pathway would also be detected. The importance
of this pathway for synthesis of either peptide is unclear although the
number ofmast cells increaseswith cardiovascular disease, for example
in atherosclerotic lesions (Ling et al., 2012).
Though NEP inhibition alone appeared as a possible therapeutic
approach to hypertension and CHF, clinical experiencewith candoxatril
and similar agents was disappointing (Ando et al., 1995; Richards et al.,
1992b, 1993; Favrat et al., 1995; O'Connell et al., 1992; Kentsch et al.,
1996). Consistent reductions in blood pressure were not obtained in
healthy volunteers and patients with hypertension (Ando et al., 1995;
Richards et al., 1992b, 1993; Favrat et al., 1995; O'Connell et al., 1992;
Kentsch et al., 1996). Infusion of thiorphan into the human forearm,
leading to local NEP inhibition, causes vasoconstriction at least in part
reversed by a co-administration of an ET receptor antagonist Haynes
and Webb, 1994; Love et al., 1996; Ferro et al., 1998). Candoxatril also
increases plasma ET-1 concentrations (Ando et al., 1995; McDowell et
al., 1997). Both these observations suggest that NEPmay also contribute
to degradation of ET-1 (Russell et al., 1996). Local vascular accumula-
tion of ET-1 may counteract the blood pressure lowering effect of an
increase in plasma natriuretic peptide concentrations after NEP inhibi-
tion, at least in healthy subjects and hypertensives (Ando et al., 1995;
Richards et al., 1992a; Ferro et al., 1998; McDowell et al., 1997). NEP
may also degrade angiotensin II and this too may counteract the hypo-
tensive effect of natriuretic peptides (Richards et al., 1992b, 1993). NEP
inhibition alone seemed to be more promising in CHF, compared to
hypertension, possibly because of themuch greater effect on circulating
natriuretic peptide concentrations in this condition (Newby et al., 1998;
Northridge et al., 1999). Even in CHF, however, a vasoconstrictor re-
sponse to systemic NEP inhibition has been observed (Kentsch et al.,
1996).
Combined NEP and ECE inhibition is a logical pharmacological
approach. Phosphoramidon is not orally active and has not beengiven systemically in humans. When infused into the human forearm
brachial artery, however, phosphoramidon causes an increase in fore-
arm blood flow, in striking contrast to the vasoconstrictor action of
local NEP inhibition alone (Ferro et al., 1998; Haynes et al., 1995;
Hand et al., 1999). This demonstrates that the vasodilator effect of inhi-
bition of ET-1 production overwhelms the vasoconstrictor action of
decreased ET-1 and angiotensin II degradation when both ECE and
NEP are inhibited simultaneously.
We employed a similar experimental approach to that used to
demonstrate the actions of ACE inhibitors (and dual NEP and ACE
inhibitors) to confirm any ECE inhibiting action of SLV-306 in vivo
(Bucchwalder-Csajka et al., 1999; Rousso et al., 1998). As discussed
earlier, NEP inhibition alone might have been expected to augment
the hypertensive effect of big ET-1 infusion. We also found that plasma
concentrations of big ET-1 increased significantly more on the SLV-306
days than on the placebo day. Furthermore, there was no significant
change in plasma ET-1 concentration during big ET-1 infusion. More-
over, the big ET-1/ET-1 ratio significantly increased consistent with
reduced conversion of big ET-1 to ET-1.
We were also able to confirm that SLV-306 is an NEP inhibitor
in vivo. SLV-306 caused a dose dependent increase in plasma ANP
concentration almost identical to that obtained with candoxatril in
healthy volunteers (i.e. an approximate doubling of plasmaANP concen-
trations with the highest dose of inhibitor) (Northridge et al., 1989;
Jardine et al., 1990).
Conclusion
In conclusion, the results suggest SLV-306 functions as a NEP inhibi-
tor, augmenting circulatingnatriuretic peptide production and as anECE
inhibitor, reducing ET-1 synthesis, which is an attractive therapeutic op-
tion in cardiovascular disease. Such an agent overcomes the limitations
of a sole NEP inhibitor, especially if used in combination with an ACE
inhibitor or angiotensin II receptor antagonist.
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